Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

not be taken to make up for any missed dose.

****For more detailed study information, please see full Prescribing Information.

(+)Numbers indicate the range of percentages in 4 studies among adult patients, with newly diagnosed Ph+ CML, patients in blast crisis, accelerated phase, and in the chronic phase after failure of interferon-alpha therapy.

About Exjade
Exjade is indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in adult and pediatric patients (aged 2 years and over). It is approved in over 100 countries including the U.S., Switzerland, Japan, and the countries comprising the European Union. The approved indication may vary depending upon the individual country.

Exjade important safety information
Exjade is contraindicated in patients with creatinine clearance <40 mL/min or serum creatinine >2 times the age-appropriate upper limit of normal; poor performance status and high-risk myelodysplastic syndromes or advanced malignancies: platelet counts <50 x 109/L;  known hypersensitivity to deferasirox or any component of Exjade.

There have been postmarketing reports of acute renal failure, hepatic failure, and cytopenias. Renal failure requiring temporary or permanent dialysis, renal tubulopathy, and interstitial nephritis have been reported. Upper gastrointestinal ulceration and hemorrhage, sometimes fatal, have been reported. Caution should be used in elderly patients due to a higher frequency of adverse reactions. Exjade is not recommended in patients with a short life expectancy (e.g., high-risk myelodysplastic syndromes), especially when co-morbidities could increase the risk of adverse events.

Skin rashes, serious hypersensitivity reactions, decreased hearing, and lens opacities have been reported. The most common adverse reactions are nausea, vomiting, diarrhea, abdominal pain, rash, non
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
9. Novartis Class Awarded $250 Million in Punitive Damages
10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... ANN ARBOR, Mich. , Aug. 26, 2014 ... pioneering the development of breakthrough oral medicines to ... science of immune modulation, today announced the appointment ... of the company,s scientific advisory board.  Dr. Singh ... and insight to advance Lycera,s multiple ongoing research ...
(Date:8/26/2014)... , Aug. 26, 2014 Trovagene, Inc. ... Generation Dx Summit; Moving Assays to the Clinic ... and Monitoring of Cell Free Tumor DNA in ... component of its Precision Cancer Monitoring (PCM) platform ... sensitivity for the detection of tumor DNA mutations ...
(Date:8/26/2014)... Cary, NC (PRWEB) August 26, 2014 ... built-in GMP processes, implemented a new pricing structure with ... better comply with cGMP and 21 CFR Part 11 ... Good Manufacturing Practices any way we can” said Rick ... the number of available users allowed customers to have ...
(Date:8/26/2014)... Ontario (PRWEB) August 26, 2014 ... Shah as its Director of Business Development. Mr. ... Spartan RX CYP2C19 System in the ... responsible for new business opportunities and strategic initiatives ... Prior to joining Spartan, Mr. Shah was the ...
Breaking Biology Technology:Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 2Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4Spartan Bioscience Names Charudutt Shah as Director of Business Development 2
... OmniSonics Medical,Technologies, Inc., a developer of advanced ... disease, announced today that it has enrolled its,first ... I is a prospective,multi-centered U.S. registry study of ... percutaneous mechanical,thrombectomy of acute deep vein thrombosis (DVT). ...
... Signalife, Inc. (Amex:,SGN - News) announced earlier ... financial commitments with respect to acquisitions of the,Company,s ... internationally, including in Japan, other parts of Asia ... the Company,s President and CEO, stated: "I anticipate,closing ...
... ... Surveillance System, EL SEGUNDO, Calif., March 17 ... has been awarded a,task order from the Centers for Disease Control ... System (NEDSS) Base System (NBS). The system helps the CDC,manage and ...
Cached Biology Technology:First Patient Enrolled in SONIC I Registry of OmniSonics Medical Technologies' OmniWave(TM) Endovascular System 2Signalife Sees Accretive Purchase and Financial Commitments 2CSC Continues Support of Centers for Disease Control and Prevention Through New Task Order 2
(Date:8/26/2014)... the University of Liverpool has recommended investing in dog owner ... and problems such as obesity in both people and their ... 1990, the researchers found that access to dog-friendly walking environments ... people to get out and take more exercise with their ... don,t take their dogs for a walk. In the UK, ...
(Date:8/25/2014)... old saying in the biofuels industry: "You can ... a new study may pave the way to ... Department,s National Renewable Energy Laboratory (NREL) demonstrates a ... of lignin into a variety of renewable fuels, ... , " Lignin Valorization Through Integrated Biological Funneling ...
(Date:8/25/2014)... of proteins that promotes virus entry into cells also ... and other viruses, University of Missouri researchers have found. ... insights into our understanding of not only HIV infection, ... Shan-Lu Liu, M.D., Ph.D., associate professor in the MU ... , The study was recently published in the ...
Breaking Biology News(10 mins):Education and dog-friendly neighbourhoods could tackle obesity 2New process helps overcome obstacles to produce renewable fuels and chemicals 2MU researchers discover protein's ability to inhibit HIV release 2MU researchers discover protein's ability to inhibit HIV release 3
... Saskatchewan's Vaccine and Infectious Disease Organization (VIDO) have developed a ... fight against a disease for which no vaccines are yet ... that this vaccination technique may be effective against HCV. The ... , The team, funded by the Canadian Institutes of ...
... and the Department of Horticulture in the College ... have developed a new procedure for the efficient ... of strawberry. The scientists have used Agrobacterium tumefaciens, ... woodland or alpine strawberry Fragaria vesca. , ...
... of molecule which they believe could ultimately lead to ... modified tobacco. Writing in Plant Biotechnology Journal, Dr Patricia ... along with researchers at the University of Warwick say ... far frustrated attempts to turn plants into economically viable ...
Cached Biology News:U of S researchers develop new vaccine candidate against hepatitis C 2Strawberries by design 2Do plants have the potential to vaccinate against HIV? 2
...
Phospho-Btk (Tyr223) Antibody...
...
... to Ki67 - Proliferation Marker, prediluted ... related nuclear protein, expressed by proliferating cells ... cycle (G1, S, G2 and M phase). ... Ki67 antibodies are useful in establishing the ...
Biology Products: